Introduction
Through their vaccine manufacturers, Brazil, the Russian Federation, India, China and South Africa have a substantial and increasing role in the global vaccine market. Together, these countries known as BRICS are increasing the production capacity for vaccines with a high global demand and vaccines that are required specifically in the developing world. BRICS are also generally replacing multinational corporations as sources of traditional vaccines -i.e. the five vaccines originally included in the World Health Organization's (WHO) Expanded Programme on Immunization 1 -and enhancing competition and lowering prices in the United Nations' and national vaccine markets.
In this paper, we analyse the growth of vaccine production, vaccine regulation and development in BRICS over the past 20 years. We evaluate the impact of that growth on the global vaccine market, by comparing vaccine production in each of the five countries in 1993 and 2013, analysing the relevant technology sources and collaborations, following the evolution of national regulatory authorities, and determining temporal trends in the numbers of vaccines prequalified by the WHO that were produced. We also identify some of the current limitations of BRICS' vaccine-related strategies and explore ways in which the international community might help reduce those limitations.
BRICS' role in the global vaccine market
The vaccines needed for the Expanded Programme on Immunization 1 and the subsequent national immunization programmes were initially sourced from both national and international manufacturers. Recombinant hepatitis B and Haemophilus influenzae type b vaccines became available in the 1980s but their production was felt too complex for many vaccine manufacturers. Three major developments subsequently influenced the global vaccine market. One was the introduction, in 2001, of highly profitable products such as the conjugate pneumococcal vaccine, which produced profits measured in billions of United States dollars (US$). 2 The second major development was the growth of funding initiatives to introduce new vaccines nearly simultaneously throughout the developing world. 3 The third major development was the emphasis placed on quality control and assurance standards for all vaccines used worldwide. This emphasis was mainly the result of the establishment of WHO's programme of vaccine prequalification in 1987 4 and that programme's collaboration with large vaccine procurement agencies such as the Supply Division of the United Nations Children's Fund (UNICEF) and the Revolving Fund of the Pan American Health Organization (PAHO). Vaccine production has become a research-based global business with high industrial standards for quality and the potential for substantial profits. In the early days of the Expanded Programme on Immunization, the prices of the traditional vaccines used in the developing world were low because multinational corporations could produce the vaccines using existing capacity that the corporations did not need to supply their more usual, higherpriced markets. As new more-profitable vaccines became available, however, most of the multinational corporations Abstract Brazil, the Russian Federation, India, China and South Africa -the countries known as BRICS -have made considerable progress in vaccine production, regulation and development over the past 20 years. In 1993, all five countries were producing vaccines but the processes used were outdated and non-standardized, there was little relevant research and there was negligible international recognition of the products. By 2014, all five countries had strong initiatives for the development of vaccine technology and had greatly improved their national regulatory capacity. South Africa was then the only BRICS country that was not completely producing vaccines. South Africa is now in the process of re-establishing its own vaccine production and passing beyond the stage of simply importing, formulating and filling vaccine bulks. Changes in the public sector's price per dose of selected vaccines, the global market share represented by products from specific manufacturers, and the attractiveness, for multinational companies, of partnership and investment opportunities in BRICS companies have all been analysed. The results indicate that the BRICS countries have had a major impact on vaccine price and availability, with much of that impact attributable to the output of Indian vaccine manufacturers. China is expected to have a greater impact soon, given the anticipated development of Chinese vaccine manufacturers in the near future. BRICS' accomplishments in the field of vaccine development are expected to reshape the global vaccine market and accelerate access to vaccines in the developing world. The challenge is to turn these expectations into strategic actions and practical outcomes.
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stopped producing the older vaccines. Fortunately, the growth of vaccine manufacturing in some of the BRICS countries has helped to keep the prices of traditional vaccines relatively low.
Vaccine manufacturers and markets in emerging economies
Some manufacturers in low-and middle-income countries have been included in WHO's vaccine prequalification programme since the programme was established. Examples include the Pasteur Institute of Senegal and some manufacturers in the formerly communist states of central and eastern Europe -represented by the Canadabased buying group, Conpharma. By 2007, nearly 50% of the manufacturers of prequalified vaccines were based in emerging economies. 5 Around that time, such economies also became key importers of new vaccines. 6 
Special characteristics of BRICS
In the early 1990s, the Children's Vaccine Initiative performed assessments in countries that could possibly play an enhanced role in vaccine supply. All five BRICS countries were included in these assessments. Recently, the BRICS group has attracted increasing attention as a market and development force -and not just for vaccines. 7 The main functional areas of vaccine development and supply comprise clinical studies and vaccine research, development, regulation and production. Four of the BRICS countries are undertaking all of these activities and the exception -South Africa -is engaged in all but production.
Vaccine production
We examined vaccine production in each of the BRICS countries between 1993 and 2013. There are no data available on the general quality of the vaccines produced in 1993 (Table 1) , although a measles vaccine produced by the Serum Institute of India was prequalified by WHO. In 1995, yellow fever vaccines produced in Brazil and the Russian Federation came from laboratories that were approved by WHO for the production of such vaccines. Table 2 tracks the development and production of WHO-prequalified vaccines by the BRICS countries between 1986 and 2013. The number of prequalified products from manufacturers in BRICS -and other emerging economies -has increased over the last two decades but appears to have levelled off in recent years.
Over our study period, vaccines from manufacturers in BRICS represented a major proportion of the purchases made via the UNICEF Supply Division (Table 3 ) and the PAHO Revolving Fund (Table 4) 
Vaccine innovation
For each of the BRICS countries, we investigated vaccine products in the pipeline and the partnerships for vaccine innovation that have been set up ( Table 6 ). The capability of each country to master intellectual property provisions that relate to vaccine development has been discussed in earlier publications.
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Pipeline products
There are some important and innovative vaccines in the pipeline in the BRICS countries, such as the conjugate vaccines being developed in India, an influenza vaccine made from virus-like particles being developed in the Russian Federation, a dengue vaccine -based on technology from the United States National Institutes of Health -being developed in Brazil, and pneumococcal conjugate vaccines being developed in both China and India. Chinese 
Partnerships
Over the study period, many partnerships between vaccine manufacturers and multinational corporations in BRICS have been established. In India, agreements with five multinational corporations account for an estimated 22% of pipeline vaccine products. 19 Five partnerships to support technology transfer in Brazil in 2006 19 included agreements for the transfer of knowhow but no licences for patents rights. Conversely, an agreement for the transfer of dengue vaccine technology, from the United States National Institutes of Health to the Instituto Butantan in Brazil, included a licence for patent rights but no explicit authorization for the transfer of knowhow. In October 2013, Brazil's government-funded Oswaldo Cruz Foundation announced that it was going to develop an affordable measles and rubella vaccine with the support of the Bill & Melinda Gates Foundation. The Brazilian Ministry of Health is allocating funds to support this plan, including US$ 727 million for the construction of a plant at the Bio-Manguinhos site to produce the vaccine.
Two vaccine manufacturers -BioManguinhos in Brazil and Biological E. in India -illustrate the use of partnerships to assess innovative technologies. Bio-Manguinhos is a state-supported institution that has been charged with providing general access to any vaccine that the national health authorities consider to be a priority, as soon as possible. To help achieve this goal, BioManguinhos is using agreements with GlaxoSmithKline, complemented by its own development activities and many collaborative activities with several universities. 19 Bio-Manguinhos has already had several technology transfer agreements with GlaxoSmithKline, relating to the development of H. influenzae type b conjugate, rotavirus and pneumococcal conjugate vaccines, as well as straight bulk-filling agreements for oral polio, measles, mumps and rubella and measles, mumps, rubella and varicella vaccines. The partnership agreement for the H. influenzae type b conjugate project specified a reference price, which was the PAHO Revolving Fund's price minus a discount for the cost of the bulk. In return, Bio-Manguinhos received technical assistance. The agreement also specified maintenance of secrecy and knowhow for 10 years and limited export to the Mercosur countries. In addition, the agreement stipulated that Bio-Manguinhos would be charged a 4-5% running royalty for 5 years from the start of selling its own product. 19 Biological 19 For this vaccine, Biological E. used innovative methods to circumvent the patent-obstructed steps in the standard production process. Biological E. now has a WHO-prequalified pentavalent product that has been brought to market at the lowest price to date and is expected to capture a large share of the global pentavalent market for 2013-2015. 23 Biological E. has also licensed technologies -from Intercell -for the development of a Japanese encephalitis virus vaccine, for which it has the rights to market in low-and middle-income countries. In August 2013 this vaccine was prequalified by WHO for use in adults, and Biological E. expects it to be licensed soon for use in children. 24 
Vaccine regulation
A vaccine manufacturer's success on the global market depends on the market's perception of the quality -or likely quality -of that manufacturer's products. 25 Much of that perception relies on an effective system of vaccine regulation. For each of the BRICS countries, we therefore investigated the functionality of the relevant national regulatory authority -as assessed by WHO, the judgements of consumers or other regulatory authorities as to the suitability for procurement of vaccines from the country, and the regulation of clinical trials of vaccines.
National regulatory authorities
The national regulatory authority of each BRICS country has been successfully assessed by WHO and four of the authorities -all but that of South Africa 27 -after an exceptional review that was triggered by the withdrawal or delisting of several Indian products from WHO's list of prequalified vaccines.
In a country that has never exported its locally produced vaccines -such as South Africa -WHO will only assess the national regulatory authority if such an assessment is requested. In such cases, it is left to the regulatory authority to publish or not to publish the results. 
Oversight of clinical trials
Each of the BRICS countries has a system for the registration of clinical trials carried out within its borders. The latest available data on the number of vaccine trials conducted (Table 7) indicate that most of the recent vaccine trials in BRICS involved new vaccines. This indicates both the dynamism of the national regulatory authorities in BRICS and the high level of innovation involved in vaccine production in most of the countries -particularly in China and India. 
Impact on vaccine prices
Current limitations
Currently, of the vaccine manufacturers in BRICS, the Indian ones are the most globally active. The Brazilian manufacturers are also quite active but those in the Russian Federation are currently more focused on upgrading facilities -to improve production capacity and compliance with international standards -than on vaccine exports. The potential impact of Chinese manufacturers, who are now entering the global market, is immense but has yet to be realized. 39 United Nations Children's Fund 23 and World Health Organization. 9, 40 In South Africa, vaccine manufacturing has been slow to develop and may have greater potential regionally than globally.
The focus of vaccine manufacturers in BRICS has been on the domestic market, the United Nations' market or both. These manufacturers are yet to make a substantial impact on several broader and potentially more profitable vaccine markets -such as those involving new vaccines and the vaccine demands and needs of wealthier countries and the private sector within their own countries and of many middle-and high-income countries. Full exploitation of such markets is likely to push the manufacturers in BRICS into harder competition with each other for supply agreements. For each such manufacturer, the risk of loss of a substantial market share to a new supplier and the frequent lack of a large portfolio of vaccines and other products -that would allow the flexibility of easy diversification -may be major challenges to the sustainability of turnover and profit.
Given the relatively low returns from their vaccines -in absolute values -and the limited markets in which they are currently active, the vaccine manufacturers in BRICS must invest a greater percentage of turnover to research and development than the multinational corporations that also produce vaccines.
With increasing links through technology transfer, outsourcing and restricted supply arrangements, the more innovative vaccine manufacturers in BRICS are becoming ever more attractive targets for mergers and acquisitions by multinational manufacturers. They are therefore at increasing risk of a loss of autonomy and national and regional focus.
Conclusion
Most of the BRICS countries are having substantial impacts on the global vaccine market, albeit to varying degrees. The production of important traditional vaccines within BRICS is contributing to the achievement of Millennium Development Goal 4. Such production is a key component in increasing access to affordable vaccines of good quality, as it allows large-scale supplies to domestic and United Nations' markets. Through collaborations with universities, donors, international partners and multinational corporations, vaccine manufacturers in BRICS have not only provided increased production capacity for important underutilized vaccines but also developed novel vaccines for specific use in low-and middle-income countries. These manufacturers rely heavily on public sector arrangements and supply agreements with United Nations' agencies. Such reliance could stop manufacturers in BRICS from reaching their full economic potential and full sustainable impact.
The same manufacturers face several other weaknesses and challenges. These include low levels of financial and technical investment in vaccine research, the need to innovate, a dependence on limited markets, and low levels of diversity in product portfolios. Among manufacturers in BRICS, the emphasis is generally more on competition -for the same limited markets and product segments -than on cooperation. The five countries represented by the BRICS acronym are far from being a coherent group. There is a real risk of the absorption and acquisition of vaccine production facilities by multinational firms and the subsequent loss of autonomy.
In general, vaccines from the BRICS countries are currently competitively priced because the manufacturing costs in BRICS are relatively low. The prices of such vaccines may have to rise, however, to allow greater investment in vaccine research and development and the use of new processes and updated facilities to produce more complex vaccines. The prices may also have to rise as the mean income per capita in the emerging economies and, therefore, the living standards expected by the workforce increase.
It is expected that China will soon emerge as a major player in the global vaccine market and that there will be increasing differentiation between the 40 This price decrease was leveraged by suppliers from a single BRICS country -India -that had high-volume capacity and the ability to profit from sales at a relatively low price point. 
Prices of other vaccines
The pentavalent vaccine story is not unique. As documented in a Médecins Sans Frontières publication, The Right Shot, 41 42 The corresponding Biological E. product, which is made using the same technology but manufactured in India, costs less than US$ 16 per dose. 43 A live attenuated vaccine based on the same strain of virus has been developed in China and has been offered to low-and middle-income countries at a price similar to measles vaccine 44 
Резюме
Влияние инвестиций стран БРИКС в разработку вакцин на мировой рынок вакцин Бразилия, Российская Федерация, Индия, Китай и Южная Африка -страны, известные как БРИКС, -добились значительных успехов в производстве, регулировании качества и разработке вакцин за последние 20 лет. В 1993 году все пять стран занимались производством вакцин, однако используемые процессы были устаревшими и нестандартизированными, с малым объемом соответствующих исследований и незначительным международным признанием продукции. К 2014 году все пять стран значительно продвинулись в разработке технологий для производства вакцин и значительно улучшили свои национальные системы регулирования данной отрасли. К этому времени Южная Африка являлась единственной страной БРИКС, которая еще не имела полноценного производства вакцин. В настоящее время Южная Африка находится в процессе восстановления собственного производства вакцин и перехода от простого импорта, составления рецептур и расфасовки вакцин.
Были проанализированы изменения в ценах государственных закупок на дозу отдельных вакцин, доля мирового рынка, представленная продукцией отдельных производителей, и привлекательность партнерства и инвестиций в компании стран БРИКС для транснациональных компаний. Результаты показывают, что страны БРИКС оказали существенное влияние на цены и доступность вакцин на рынке, причем в основном это относится к продукции индийских производителей вакцин. Ожидается, что Китай также будет наращивать свое влияние, учитывая ожидаемое развитие китайских производителей вакцин в ближайшем будущем. Ожидается, что достижения стран БРИКС в области разработки вакцин приведут к изменению мирового рынка вакцин и ускорению доступа к вакцинам в развивающихся странах. Задача состоит в том, чтобы воплотить эти ожидания в стратегические действия и практические результаты.
Resumen
El impacto de la inversión de los BRICS en el desarrollo de vacunas sobre el mercado mundial de vacunas
Brasil, la Federación de Rusia, India, China y Sudáfrica, los países conocidos como BRICS, han hecho progresos considerables en la producción, regulación y desarrollo de vacunas en los últimos 20 años. En 1993, los cinco países ya producían vacunas, pero los procesos empleados para ello estaban anticuados y sin normalizar, había poca investigación relevante y un reconocimiento internacional mínimo de sus productos. En 2014, los cinco países contaban con iniciativas sólidas para el desarrollo de la tecnología relacionada con las vacunas y habían mejorado en gran medida su capacidad normativa nacional. Sudáfrica fue el único de los BRICS que no fabricaba vacunas en su totalidad. En la actualidad, dicho país se encuentra en proceso de restablecer su propia producción de vacunas e ir más allá de la simple importación, formulación y llenado de lotes de vacunas. Se han analizado los cambios en los precios por dosis de vacunas seleccionadas del sector público, la cuota de mercado mundial de productos de fabricantes específicos y el atractivo para las empresas multinacionales de la asociación y las oportunidades de inversión en empresas de los BRICS. Los resultados indican que los países BRICS han tenido un gran impacto en el precio y la disponibilidad de las vacunas, y que una gran parte de ese impacto se puede atribuir a la producción de vacunas de los fabricantes de India. Se confía en que China tenga pronto un impacto mayor, dada la evolución prevista de los fabricantes de vacunas chinos en el futuro cercano. Se espera que los logros de los BRICS en el campo del desarrollo de vacunas remodelen el mercado mundial de las vacunas y aceleren el acceso a las mismas en el mundo en desarrollo. El desafío consiste en convertir estas expectativas en actuaciones estratégicas y resultados prácticos.
